anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention is based on the pioneering finding that inhibition of expression of certain genes counteracts the cytokine-induced cell death. As long as these genes function normally, cytokine induces cell death; once the expression of said genes in inhibit, the cytokine-induced cell death is inhibited. It follows therefrom that the normal expression is cytokine-induced cell death. In HeLa cells IFN-y induces a biphasic process, which comprises an initial cytostatic phase and a subsequent cytotoxic phase (programmed cell death). The novel genes discovered in accordance with the present invention were found to affect only the later, cytotoxic phase. These genes, referred to as "DAP" (death-associated protein) genes, include DNA molecules which comprise a coding sequence encoding the expression products of the DAP genes or expression products having a similar biological activity, and are at times collectively referred to as "DAP DNA molecules". The expression products of the DAP DNA molecules will be referred to herein at times collectively as "DAP products".
A healthy product beneficial to the removal of nicotine in human body and the preparation method thereof belong to the field of healthy product technology. The invention is used for eliminating or alleviating the damage on human body by smoking. The technical scheme comprises following steps: selecting 450 to 470 parts of Polygonum lapathifolium and 120 to 150 parts of Flos Lonicerae, pulverizing, blending, etc. The healthy product is prepared from natural plants and precious medicinal materials and contains no chemical substances such as additives and preservatives. The preparation can be sprayed to the tobacco or the cigarette holder to eliminate or alleviate the damage of nicotine on human body. The product has certain promotion effects on reducing the incidence rate of patients with respiratory diseases and improving immune function of human body. Additionally, the product can be added into various kinds of snack food to prepare healthy food for common people.
Auricular point with Vaccaria seed was attached to the earlobe, which is the place with the least vagal innervation. Ear pressure therapy depends on the patient's gas state (acid, numbness, heaviness, bloating, etc.). ). Frequency: Press the auricular points three times a day within half an hour after meals for about 1-2 minutes, and press the auricular points for about 30 times. Press the bilateral earlobes alternately. The treatment lasted for 2 weeks. Go to the hospital to change the ear patch once a week.
1291644 Substituted 1-indanecarboxylic acids, esters and salts BRISTOL-MYERS CO 30 Jan 1970 [31 Jan 1969] 4535/70 Heading C2C The invention comprises d-, l- and dl-compounds of formula and nontoxic pharmaceutically acceptable salts and C 1-6  alkyl and (up to C 8 ) tertiary amino alkyl esters thereof, wherein Y is H, Cl, Br, F, OH, C 1-6  alkyl, alkoxy or alkylthio, SH, CN, NO 2  or NH 2 . These compounds are prepared by reacting p - cyclohexylphenylsuccinic anhydride [from the acid, itself made via p-cyclohexylbenzaldehyde, diethyl p-cyclohexylbenzylidenemalon. ate and ethyl 3-cyano-3-(p-cyclohexylphenyl)- propionate] with a Friedel-Crafts catalyst in an inert organic solvent to give 5-p-cyclohexyl-3- oxoindan-1-carboxylic acid, and reducing the latter, and where desired producing the compounds where Y is other than H by standard substitution methods (optionally preceded or followed by esterification using the acid or acid chloride); including nitration, reduction of the nitro-compound and utilization. of the intermediate where Y is a diazonium group (II). Circhonidine and dehydroabietylamine salts are used in examples for optical resolution. The compound where Y=HS may be prepared by saponifying the intermediate in which Y= EtOCS 2 -(obtained from II). The intermediate of the above formula where Y=I is also mentioned. Therapeutic compositions for oral or parenteral administration comprise compounds of the above formula, which are anti-inflammatory agents.
The present invention relates to a system for assessing whether an error situation in nursing is recognized based on virtual reality (VR). According to embodiments of the present invention, the system for assessing whether an error situation in nursing is recognized based on virtual reality comprises: a storage unit to store scenario images including an error image; and a control unit to determine whether a person to be assessed recognizes a screen of an error image when the screen of the error image is displayed while watching stored scenario images to assess whether the person to be assessed recognizes an error situation in nursing based on VR. And use of education content is possible for nursing students or nurses to lower accident rates and improve safety consciousness. Also, efficient education training and assessment are possible by realistic devices only without being limited by space by realizing a virtual practice environment. A multi-education training assessment system capable of deriving assessment results immediately after education assessment for whether an error situation is recognized at the same time of virtual education training can be developed. The present invention can be replaced as a main teaching material and an error recognition education assessment system of education training across all fields in each industry requiring education training by using audio and video.
STUDY DESIGN: This is a cross-sectional survey.
OBJECTIVE: The aim was to assess the reliability of a proposed novel classification system for thoracic disc herniations (TDHs).
SUMMARY OF BACKGROUND DATA: TDHs are complex entities varying substantially in many factors, including size, location, and calcification. To date, no comprehensive system exists to categorize these lesions.
METHODS: Our proposed system classifies 5 types of TDHs using anatomic and clinical characteristics, with subtypes for calcification. Type 0 herniations are small (≤40% of spinal canal) TDHs without significant spinal cord or nerve root effacement; type 1 are small and paracentral; type 2 are small and central; type 3 are giant (>40% of spinal canal) and paracentral; and type 4 are giant and central. Patients with types 1 to 4 TDHs have correlative clinical and radiographic evidence of spinal cord compression. Twenty-one US spine surgeons with substantial TDH experience rated 10 illustrative cases to determine the system's reliability. Interobserver and intraobserver reliability were determined using the Fleiss kappa coefficient. Surgeons were also surveyed to obtain consensus on surgical approaches for the various TDH types.
RESULTS: High agreement was found for the classification system, with 80% (range 62% to 95%) overall agreement and high interrater and intrarater reliability (kappa 0.604 [moderate to substantial agreement] and kappa 0.630 [substantial agreement], respectively). All surgeons reported nonoperative management of type 0 TDHs. For type 1 TDHs, most respondents (71%) preferred posterior approaches. For type 2 TDHs, responses were roughly equivalent for anterolateral and posterior options. For types 3 and 4 TDHs, most respondents (72% and 68%, respectively) preferred anterolateral approaches.
CONCLUSIONS: This novel classification system can be used to reliably categorize TDHs, standardize description, and potentially guide the selection of surgical approach. Validation of this system with regard to treatment and clinical outcomes represents a line of future study.
The present invention describes the identification of a novel protein P-SCGB  belonging to the family of uteroglobins/secretoglobins, and nucleic acid sequences encoding said protein. Said protein and nucleic add sequences are useful in the diagnosis and/or treatment of lung injuries and diseases, and of inflammation or immunomodulation-related disorders. More particularly said protein and nucleic add sequences are useful in the diagnosis and/or treatment of asthma. The new protein is specific for the lung and has a small size facilitating its transepithelial leakage from the lung into serum. It therefore has all the features to serve as a peripheral lung marker.  Furthermore, its homology with members of the uteroglobin/secretoglobin family make it a potentially important protein that may be used as a diagnostic or therapeutic tool for many other pathologies.
Chronic overlapping pain conditions (COPCs) refer to conditions that have similar central nervous system pathophysiologic mechanisms driving widespread pain as well as common comorbid symptoms such as fatigue and problems with sleep, memory, and mood. If COPCs predict the onset of long COVID, this could offer a valuable orientation for long COVID-related research and clinical care. This retrospective cohort study aimed to determine whether having a COPC predicts the onset of long COVID features using US electronic health records and 1:1 propensity score matching without replacement. The study cohorts included (1) people with acute COVID (n = 1,038,402), (2) people with acute influenza (n = 262,092), and (3) a noninfected cohort comprising people with a routine healthcare encounter (n = 1,081,593). Having a COPC increased the risk of long COVID features in all 3 study cohorts. Among those with COVID, having a pre-existing COPC increased the risk by 1.47 (95% CI = 1.46, 1.47). In the influenza cohort, COPCs increased the risk by 1.39 (95% CI = 1.38, 1.40). In the noninfected cohort, COPCs increased the risk by 1.57 (95% CI = 1.56, 1.59). These findings reinforce the likelihood that nociplastic mechanisms play a prominent role in long COVID. Recognizing that this ubiquitous nonspecific syndrome occurs frequently in the population can inform precision medicine therapies that avoid the pitfalls of viewing long COVID exclusively in the framework of postinfectious disease.
Nurses in the control group did not receive simulated situational teaching, but received classroom teaching 3 times (once every other week) (delirium assessment, risk factor assessment; PADIS treatment), each session of about 2 hours. In order to avoid inconsistent teaching content, the control group and the experimental group are not to be together in classroom.
A medical system (10) and method monitor a patient. Patient data for the patient received. The patient data includes vital sign measurements and laboratory results. A vital signs instability index (VIX) regarding a physiological condition of the patient is calculated from the received vital sign measurements. A laboratory instability index (LIX) regarding the physiological condition is calculated from the received laboratory results. The VIX and the LIX are integrated into an indicator of patient deterioration.
In a cardiovascular outcomes trial enrolling participants with established ASCVD or multiple risk factors for ASCVD (SAVOR trial), more patients randomized to saxagliptin (289/8280, 3.5%) were hospitalized for heart failure compared to patients randomized to placebo (228/8212, 2.8%). In a time-to-first-event analysis the risk of hospitalization for heart failure was higher in the saxagliptin group (estimated Hazard Ratio: 1.27; 95% CI: 1.07, 1.51). Subjects with a prior history of heart failure and subjects with renal impairment had a higher risk for hospitalization for heart failure, irrespective of treatment assignment.

Consider the risks and benefits of saxagliptin prior to initiating treatment in patients at a higher risk for heart failure. Observe patients for signs and symptoms of heart failure during therapy. Advise patients of the characteristic symptoms of heart failure and to immediately report such symptoms. If heart failure develops, evaluate and manage according to current standards of care and consider discontinuation of saxagliptin.
Topical antiseptic nibs are disclosed that reduce microorganism loading on the skin surface preventing possible infections. The FDA currently recognizes ethanol, isopropanol and benzalkonium chloride as active ingredients but further defines the actives as chronic use drugs. The present invention describes formulations and applications of a liquid compound that forms a topical polymeric skin layer consisting of a given benzalkonium chloride concentration within the matrix, which quickly reduces all bacteria including the MERS, virus types, and kills spores including the Clostridium difficle. The "second skin" concept, is likened to the human skin cellular function of the stratum corneum, functions as a barrier to exogenous substances, which reduces any chronic flux of benzalkonium chloride into the epidermis and reducing symptoms of constant usage. The second skin polymeric application agglomerates, traps and kills bacteria. The "second skin" provides for cosmetic moisturizing, barrier effects and skin softness.
Participants in this group were randomly allocated to receive a perineural catheter placed at the time of adductor canal block (ACB). The ACB was performed under ultrasound guidance and a 10ml injection of 0.5% bupivacaine was administered adjacent to the saphenous nerve. A PERINEURAL CATHETER WAS INSERTED IMMEDIATELY AFTER INJECTION OF THE INITIAL BOLUS OF LOCAL ANAESTHETIC. THE CATHETER WAS CONNECTED TO A PAJUNK FUSERPUMP CONTAINING 350 ML OF 0.15625% BUPIVACAINE AND INFUSED AT 8ML/HR.
The present invention relates to a bilobanoate oral disintegrating tablet and a preparation method thereof. The tablet is mainly prepared from components of the following shares by weight: 2 to 40 shares of bilobanoate, 1 to 20 shares of disintegrating agent and 2 to 100 shares of bulking agent. The preparation method which is disclosed by the present invention is simple. Prepared bilobanoate oral disintegrating tablet can be dissolved in a small quantity of water, and disintegrated in short time. The tablet has good mouth feel. The compliance of patients who need taking medicines for a long time is largely improved, so therapeutic effect is guaranteed.
The invention provides application of circulating plasma miR26b-3p as a biomarker in preparation of a kit for diagnosing abdominal aortic aneurysm. The invention also provides application of the reagent for detecting the circulating plasma miR26b-3p in preparation of a kit for diagnosing the abdominal aortic aneurysm. The invention also provides application of the miR26b-3p activator agomir in preparation of a medicament for treating abdominal aortic aneurysm. The invention also provides application of miR26b-3p as a drug target in screening of drugs for treating abdominal aortic aneurysm. Overexpression of miR26b-3p can effectively inhibit formation and rupture of abdominal aortic aneurysm. Experiments show that miR26b-3p is obviously down-regulated in abdominal aortic aneurysm tissues and blood plasma, and miR26b-3p circulating in blood has good detection and diagnosis values.
The active control group will participate in three 30-minute, supervised, remotely-delivered classes targeting balance and flexibility. The program will be delivered at a low-intensity by a Registered Kinesiologist via videoconferencing (i.e., Zoom). Participants will be asked to participate in the program for 8 weeks.
The method for validating an antimicrobial combination for drug-resistant bacteria comprises identifying a combination of two or more antimicrobial agents with synergistic activity; an in vitro resistance study; an in vivo efficacy study; an in vivo toxicity study; and a pharmacokinetic and pharmacodynamic study with humans. The method may comprise a checkerboard assay or a time-kill assay. The in vivo studies may use a murine model or rats. The bacteria may show resistance in patients from the northern hemisphere or the southern hemisphere. The bacteria may be colistin-resistant, and the combination may include colistin. The bacteria may be multi-drug resistant. Also claimed is an antimicrobial combination obtained from the method.
The How-to Parenting Program is a highly structured and skill-based program. It is manualized, teaches 30 concrete, specific, easy-to-grasp (e.g., taught using comic strips), and readily applicable skills. It also optimizes learning with exercises (e.g., perspective taking; role-playing) and practice, and addresses parents' readiness and motivation to change. The program is delivered over six consecutive 2-hour weekly sessions (12 hours in total).
Asthma is a chronic inflammatory disorder of the airways characterized by reversible airflow obstruction. Fourteen million people (6.4%) in the United States report having asthma, and from 1980 to 1994 the prevalence of self-reported asthma in the United States increased 75%. Interleukin-4 (IL-4) plays a key role in this response by promoting IgE production, upregulating IgE receptors, upregulating adhesion receptors such as VCAM-1, promoting Th2 cell development and promoting mucus secretion. A soluble form of the receptor for IL-4 (IL-4R) that has antagonist activity has been developed for clinical use. Soluble IL-4R acts by competing with endogenous cell bound IL-4R for free IL-4, thus inhibiting IL-4 function. IL-4 is required for the development of allergen specific Th2 memory cells. Less well understood are the factors required for maintenance of Th2 responses. The maintenance of polarized Th2 responses to allergens have been postulated to require IL-4 itself, by acting as an anti-apoptotic/survival factor or by differentiating naive allergen specific T cells to the Th2 phenotype. Subjects on sIL-4 therapy represent a unique patient group that possess allergen specific Th2 cells, but in which the capacity for IL-4 to promote further Th2 cell survival or differentiation has been blocked. This is a single site adjunct study proposed to study subjects ages 14 years and older who are enrolled at the NIH Clinical Center on a multicenter trial of IL-4R in moderate to severe asthma (Phase II Efficacy Study of Aerosolized Recombinant Human IL-4 Receptor in Asthma). A maximum of 40 subjects will be enrolled. We hypothesize that effective blocking of such Th2 priming would result in a decreased frequency of both allergen specific Th2 cells as well as mitogen activated Th2 cells. Determination of the fate of Th2 cell responses during long term IL-4R therapy may have important implications both for future development of anti-cytokine therapies as well as for understanding the T cell biology of allergic diseases and asthma.
PCT No. PCT/DK93/00100 Sec. 371 Date Sep. 16, 1994 Sec. 102(e) Date Sep. 16, 1994 PCT Filed Mar. 18, 1993 PCT Pub. No. WO93/18668 PCT Pub. Date Sep. 30, 1993A salt product comprising particles of NaCl, K/Mg-double salts and optionally KCl homogeneously distributed throughout each particle and having a molar ratio of K to Mg>/=1. The product may be obtained from an aqueous salt mixture, preferably a solution containing the desired proportion of salt ions and having a water content of 50 to 90% by weight by subjecting the aqueous salt mixture to instant drying at a temperature of 70 DEG  to 200 DEG  C. for a period of 1 to 60 seconds to obtain a dry product. The product is usable as a low sodium substitution for common salt in connection with the preparation of food, beverages or pharmaceutical products and/or as a preservative or water binding agent.
In the second stage of the research, swimmers were subjected to the 8x100 m freestyle maximum effort swimming test on the same day and time of the week after consuming a placebo drink. The swimmers' blood lactate values and fatigue scale were reapplied using the same procedure. After the analysis of the results of the placebo intervention, beetroot juice drinks were distributed to the swimmers to be used in the third stage. Swimmers were asked to consume 2x250 ml of beet juice on weekdays and 1x250 ml on Saturdays before the performance test. Swimmers consumed beetroot juice 2.5 hours before training on double training days. On single training days during the week, the patient was asked to consume 2x250 ml of beetroot juice at similar times to other days.
Falls are prevalent among older adults and can cause serious problems. Falls in older adults can cause serious injuries that negatively impact their quality of life and can be life-threatening. Evaluating an individual's risk of fall is, typically, an important first step in preventing falls. Fall risk is commonly evaluated through clinical measurement scales, such as the Tinetti Performance Oriented Mobility Assessment (POMA) and Berg Balance Scale (BBS). Physical measurements using instruments, such as inertial measurement units (IMUs; accelerometers and gyroscopes) and force plates, can also be employed to evaluate an individual's fall risk. However, both clinical and instrumented measures are often only collected in clinical or research settings, thus making them less accessible to older adults and their care providers. Additionally, fall risk can only be evaluated infrequently, which can be a problem as health and environmental changes in the life of an older adult can necessitate more frequent measurement of fall risk. The research team proposes consumer-grade wearable devices (e.g. smartphones and watches) to fill the gap in current fall risk assessment. This approach has great potential as quick, simple, timely, and frequent measures of fall risk can help to reduce fall risk in older adults. The proposed research investigates older adults' gait and balance to identify potential links between wearable sensor measurements and fall risk. The types and granularity of data on physical activities that can be collected by consumer-grade wearable devices are more limited than using research-grade measurement. The investigators plan to use research-grade sensors to validate measures of gait and balance via consumer-grade wearable devices. Signal processing algorithms will be employed to extract the critical patterns from wearable device measurements that could be used for regular fall risk monitoring. A machine-learning computational model will also be developed to correlate the wearable data to clinical scales. This data will be used to design and build a mobile app for older adults to self-administer the fall risk test at home. The application design will be informed by factors such as one's physical environment, health condition, fear of falls, etc. and the goal is to develop an integrated system that offers fall risk assessment and provides alerts for older adults.
Cardiopulmonary exercise testing (CPET) using a Quark CPET metabolic cart (Rome, Italy) according to American Thoracic Society (ATS) guidelines. A symptom-limited test on a treadmill will be performed, using incremental ramp Bruce protocol up to exhaustion. Patients who will not be able to perform the test on a treadmill will be tested on a cycle ergometer beginning with a no-resistance warm-up lasting 2-3 minutes, followed by incrementing resistance (8-30 Watts/minute) adapted to the patient's functional capacities according to the examiner's free judgment, up to exhaustion.
The invention relates to the novel pharmaceutical application of PVP, which belongs to the technical field of the medicine. The PVP belongs to the water-soluble polymer, and is easily soluble in polar organic solvent, such as water and ethanol. The PVP is usually adopted as the adhesive of the oral solid preparation, the thickener in liquid oral preparation and the adhesive, the retardant and the penetration enhancer in sustained and controlled release preparation. The PVP can be taken as the porogenic agent for the formulation design of the oral osmotic pump preparation. By taking the PVP as the porogenic agent, coating membrane can be brighter than the coating membrane with PEG as the porogenic agent, and the appearance is better. The PVP has good characteristics when being adopted as the porogenic agent, thereby the PVP is a good substitute for polyethylene glycol as the porogenic agent. By adopting the PVP, the water permeation ratio of the porogenic agent can be adjusted, thereby the release rate of the medicine can be adjusted.
Includes age group 5-10 with a cap at 50 subjects. This is a retrospective, observational study.